Overview

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy of the combination of gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in patients with metastatic pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborator:

Hoffmann-La Roche

Treatments:

Capecitabine
Erlotinib Hydrochloride
Gemcitabine